Showing results (401-410 of 447) with videos related to
Sort By:
Pageof 45
Genome Medicine|October 27, 2016
Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trialTracy L Stockley, Amit M Oza, Hal K Berman, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 21, 2018
Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung CancerYasushi Yatabe, Sanja Dacic, Alain C Borczuk, et al.Lancet (London, England)|November 6, 2023
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trialQuincy Chu, Francesco Perrone, Laurent Greillier, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 25, 2023
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)Maria Carmela Piccirillo, Quincy Chu, Penelope Bradbury, et al.Pathology|March 29, 2021
The concept of mesothelioma in situ, with consideration of its potential impact on cytology diagnosisSonja Klebe, Yukio Nakatani, Katalin Dobra, et al.Nature Chemical Biology|February 26, 2020
A drug discovery platform to identify compounds that inhibit EGFR triple mutantsPunit Saraon, Jamie Snider, Yannis Kalaidzidis, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 14, 2017
The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program EfficiencySonya Cressman, Stuart J Peacock, Martin C Tammemägi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 4, 2021
The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLCMari Mino-Kenudson, Nolwenn Le Stang, Jillian B Daigneault, et al.Nature Communications|January 19, 2019
ONECUT2 is a driver of neuroendocrine prostate cancerHaiyang Guo, Xinpei Ci, Musaddeque Ahmed, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 9, 2025
Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung CancerMihaela Aldea, Julia K Rotow, Maria Arcila, et al.Pageof 45